Skip to main content
Premium Trial:

Request an Annual Quote

Imagining the Future

US News and World Report's Bernadine Healy imagines how cancer will be treated in 2040 and discusses how close we are today to making cancer a chronic disease whose treatment is tailored to the patient. Healy seems hopeful that the Cancer Genome Atlas project will help elucidate the genetic causes of cancer.

Also on the cancer front, David Dooling blogs about a talk given by Memorial Sloan-Kettering's Chris Sander. Sander studies cancer at different biological levels, from SNPs to signaling pathways, and how drugs affect those pathways. "The question still remains however: pathways-level analysis will cover 60-80% of people with a specific sub-type of cancer. What about the other 20-40% whose mutations don’t fall into those pathways?" Dooling asks.


The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.